Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the ...

Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology -- Two new ...

Penn Ovarian Cancer Research Center and Basser Center for BRCA, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States ...

Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...

"A highlight of the third quarter was the presentation of our validating COM701, COM902, pembrolizumab combination data in heavily pre-treated platinum resistant ovarian cancer (PROC ... more fully ...

Given in combination with chemo, the Zynyz regimen reduced the risk of disease progression ... phase 1b study reported at ESMO. Incyte is highlighting the ovarian cancer cohort of 37 evaluable ...

Researchers from the Walter and Eliza Hall Institute (WEHI)in Australia have found a new way to predict a subset of patients ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

A gynaecologist has highlighted that many women might not recognise the early warning signs of ovarian cancer, which is the sixth most prevalent cancer among UK women, according to Cancer Research ...

“Thus, current guidelines focusing on early HCC detection may be missing opportunities for screening, early detection, and ...

ovarian cancer progressing under taxane/carboplatin chemotherapy or in early relapse (< 6 months).

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia ... Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab ...